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Abstract
Objective To evaluate risk factors for severe outcomes in patients with
seasonal and pandemic influenza.
Design Systematic review.
Study selectionObservational studies reporting on risk factor-outcome
combinations of interest in participants with influenza. Outcomes included
death, ventilator support, admission to hospital, admission to an intensive
care unit, pneumonia, and composite outcomes.
Data sources Medline, Embase, CINAHL, Global Health, and the
Cochrane Central Register of Controlled Trials to March 2011.
Risk of bias assessment Newcastle-Ottawa scale to assess the risk
of bias. GRADE framework to evaluate the quality of evidence.
Results 63 537 articles were identified of which 234 with a total of 610
782 participants met the inclusion criteria. The evidence supporting risk
factors for severe outcomes of influenza ranged from being limited to
absent. This was particularly relevant for the relative lack of data for
non-2009 H1N1 pandemics and for seasonal influenza studies.
Limitations in the published literature included lack of power and lack of
adjustment for confounders was widespread: adjusted risk estimates
were provided for only 5% of risk factor-outcome comparisons in 39 of
260 (15%) studies. The level of evidence was low for “any risk factor”
(odds ratio for mortality 2.77, 95% confidence interval 1.90 to 4.05 for
pandemic influenza and 2.04, 1.74 to 2.39 for seasonal influenza), obesity
(2.74, 1.56 to 4.80 and 30.1, 1.74 to 2.39), cardiovascular diseases
(2.92, 1.76 to 4.86 and 1.97, 1.06 to 3.67), and neuromuscular disease
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(2.68, 1.91 to 3.75 and 3.21, 1.84 to 5.58). The level of evidence was
very low for all other risk factors. Some well accepted risk factors such
as pregnancy and belonging to an ethnic minority group could not be
identified as risk factors. In contrast, women who were less than four
weeks post partum had a significantly increased risk of death from
pandemic influenza (4.43, 1.24 to 15.81).
Conclusion The level of evidence to support risk factors for influenza
related complications is low and some well accepted risk factors,
including pregnancy and ethnicity, could not be confirmed as risks.
Rigorous and adequately powered studies are needed.
Introduction
Influenza is a major global cause of illness and death, resulting
in an estimated three to five million cases of severe influenza
illness and 250 000 to 500 000 deaths annually.1-3 The risk of
complications from influenza, including lower respiratory tract
infection, admission to hospital, and death vary depending on
factors such as age and the type of comorbidity that may be
present.1 2 Currently, the World Health Organization and most
countries prioritise specific high risk groups for vaccination.2-6
Although some recommendations are consistent, such as
vaccination of healthcare workers, pregnant women, and those
with certain high risk conditions, there are also discrepancies,
such as the age groups that need to be prioritised (table 1⇓).
Despite the widely accepted public health policy of
recommending vaccination to groups believed to be at high risk
for complications of influenza, a comprehensive and systematic
review of the evidence defining these groups is lacking.
Assessment of the quality of evidence supporting these risk
groups and identifying the most important risk groups is
essential when making decisions about the allocation of
influenza vaccination and antiviral therapy, and planning about
health system utilisation. We summarised this evidence for
seasonal and pandemic influenza.
Methods
All decisions regarding eligibility criteria, search strategy, study
selection, assessment of risk for bias, explanations for
heterogeneity, data collection, and analysis were established a
priori.
Eligibility criteria
We included studies reporting on at least one risk factor-outcome
combination in participants with evidence of influenza infection.
The latter included laboratory confirmed influenza or the
presence of influenza-like illness during a period of known
influenza circulation. Studies on H5N1 avian influenza were
considered but are not reported here. Eligible study designs
included randomised controlled trials, cohort, case-control, and
cross sectional. We included case series if participants with and
without a specific outcome for a particular risk factor were
reported, and we considered studies in English, French, German,
Spanish, and Korean, based on the language skills of the study
team. We excluded case reports.
Outcomes
Outcomes of interest included community acquired pneumonia,
mortality, admission to hospital, admission to an intensive care
unit, need for ventilator support, and any composites consisting
of all or some of these outcomes. We chose these outcomes
because they are patient important, most commonly reported in
studies reporting on severe outcomes of influenza, and used for
the clinical assessment in interventional studies on influenza.7 8
We defined community acquired pneumonia as involvement of
the lower respiratory tract within 72 hours of hospital admission
or according to the criteria in the original study. Ventilator
support was defined as the need for respiratory support beyond
applying oxygen alone.
Risk factors
We used the age categories that were most commonly reported
in the original articles: >65 years for elderly, <18 years for
children, 2 to <5 years, <2 years, and <6 months. If other
categories were reported, we chose the closest to these cut-offs.
We compared other ethnic groups with white participants.
Definitions of comorbidities by the original studies were used.
Obesity was defined as a body mass index of >30 kg/m2 or as
defined by the original studies.
Search strategy and data extraction
We searched Medline, Embase, CINAHL, Global Health, and
the Cochrane Central Register of Controlled Trials (CENTRAL)
up to 25 March 2011. The search strategy was created in
collaboration with a librarian (NB) and included a combination
of keywords and subject headings for all major concepts (see
supplementary appendix A). We also searched reference lists
of identified articles and review articles.
We screened titles or abstracts and full text articles, extracted
data using a standardised and piloted electronic database, and
assessed risk of bias. Pairs of reviewers independently conducted
all the steps. A third reviewer (DM) resolved any disagreement
between reviewers by consensus or arbitration.
Quality assessment
We used the Newcastle-Ottawa scale to assess the risk of bias
in observational studies.9 This scale allocates up to 9 points for
the least risk of bias in four domains: selection of study groups
(4 points), comparability of groups (2 points), and ascertainment
of exposure and outcomes (3 points). Vaccination status for
influenza and antiviral treatment were defined as the most
important covariates that would define comparability.
We evaluated the quality of evidence for each risk factor using
criteria selected from the grading of recommendations
assessment, development, and evaluation (GRADE)
framework.10 GRADE is a standardised approach to assess the
quality of evidence, and ranges from very low to high. Two
researchers (DM and JJ) independently assessed the GRADE
of evidence by combining pandemic and seasonal influenza and
considering all outcomes but giving additional weight to death.
Meta-analyses
Assuming that heterogeneity exists in findings across studies,
we adopted a random effects model in Review Manager 5.0
(Cochrane Collaboration)11 to obtain a summary estimate of the
average effect with its 95% confidence interval.12 We used
Stata/IC 11.2 (StataCorp LP, Texas, USA) to calculate the 95%
prediction intervals. The width of prediction intervals is affected
by the uncertainty in the summary estimate and by the estimate
(and its uncertainty) of the between-study standard deviation
of the true effect, and prediction intervals are therefore affected
by the heterogeneity across the studies.12
If risk estimates alone and no data were reported, we pooled the
individual studies using the inverse variance method and
converted to odds ratios and 95% confidence intervals in a
secondary analysis.13We pooled case-control studies separately,
whereas we included cross-sectional studies in themeta-analyses
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2013;347:f5061 doi: 10.1136/bmj.f5061 (Published 23 August 2013) Page 2 of 16
RESEARCH
of cohort studies. Meta-analyses were performed overall and
separately for pandemic and seasonal influenza. The I2 statistic
was used to evaluate heterogeneity.14We explored heterogeneity
between subgroups that were defined a priori (according to place
of enrolment, risk of bias, laboratory confirmation of influenza,
influenza vaccination status) whenever I2was greater than 60%.15
The term used to define the place of enrolment included
“community” (participants presenting in an outpatient setting
at enrolment), “hospital” (participants admitted to hospital in a
non-intensive care unit setting), and “intensive care unit”
(participants admitted to hospital in the intensive care unit).
Publication bias was assessed by visual interpretation of funnel
plots and the Egger’s test16 and, as a sensitivity analysis, with
the test by Harbord.17
Results
We identified 63 537 citations in the search of electronic
databases and an additional 16 citations by searching
bibliographies of relevant articles (figure⇓). A total of 239
studies described in 234 articles met our eligibility criteria,
comprising data on 610 782 participants (table 2⇓, see
supplementary appendix B). The majority were cohort studies
(n=231, 97%) that used laboratory confirmation to ascertain
influenza infection (n=220, 92%) and most were conducted
during pandemic influenza seasons (n=183, 77%). Since only
six studies (3% of all studies) with 1278 participants (0.2% of
the study population) were case-control studies, tables 3⇓ and
4⇓ present the results of only cohort studies. No studies included
in the final synthesis needed to be excluded because of a failure
to report either odds ratios and the 95% confidence intervals or
raw data from which the odds ratios could be calculated. The
summary estimates reported here were based on unadjusted risk
estimates.
Risk of bias and quality of evidence
assessment
The Newcastle-Ottawa scale scores for risk of bias ranged from
1 to 8 out of a maximum of 9, with a median of 6 across studies
(table 2). Notably, adjusted risk estimates were provided for
only 152 of 2788 (5.4%) risk factor-outcome comparisons in
39 of 260 (15%) studies. Because of the limited availability of
adjusted risk estimates and the diversity of covariates adjusted
for, meta-analyses of adjusted risk estimates were not conducted.
However, when they were available, adjusted and crude odds
ratio estimates were similar.
Based on an adaptation of the GRADE approach to assess the
quality of evidence, our confidence in risk estimates was low
for the presence of “any risk factor,” obesity, any cardiovascular
disease, and any neuromuscular disease, and very low for all
other risk factors (table 5⇓). All major risk factors with multiple
studies were downgraded because of study quality, as their
median Newcastle-Ottawa scale score was always below 7.
Inconsistency and imprecision were also common for most
major risk factors (tables 3-5). For a given risk factor we would
have expected consistency of associations with all outcomes.
Thus, we considered heterogeneity in findings across outcomes
within risk groups to be inconsistent usingGRADEmethodology
as was heterogeneity across studies for each risk factor-outcome
combination.
While the presence of heterogeneity and the small number of
studies for each risk factor-outcome comparison limited the
ability to assess the risk of publication bias, there was no
convincing evidence of publication bias for the risk
factor-mortality combinations that were deemed to be at low
level of evidence. The presence of publication bias would not
have further decreased the level of evidence for risk factors
already deemed to be very low.
Seasonal influenza
Age as a risk factor
We found a significant increase in the risk of death among
elderly people compared with non-elderly people (odds ratio
2.95, 95% confidence interval 1.53 to 5.70, I2=11%, n=4) (table
3). Elderly participants also had a higher risk of admission to
hospital. Children aged less than 5 years were at lower risk of
death (0.40, 0.20 to 0.80, I2=0%, n=8), had lower hospital
admission rates, and were less likely to need ventilator support
than older children but were at higher risk of developing
pneumonia. When very young children (<2 years of age) were
compared with the other age groups, they were at significantly
lower risk for admission to hospital, admission to an intensive
care unit, and the need for ventilator support.
Ethnicity and pregnancy
Data on ethnicity was rare for seasonal influenza, and no
ethnicity studied was associated with a significant higher risk
for severe outcomes. In contrast with pandemic influenza,
pregnancy as a risk factor was not well studied for seasonal
influenza, with only one study having data on this with no
significant association with death.
Comorbidity
Based largely on comorbidity, the presence of “any risk factor”
was significantly associated with death (2.04, 1.74 to 2.39,
I2=0%, n=4), pneumonia, hospital admission, and admission to
an intensive care unit. Only one seasonal influenza study with
a small event rate provided data on obesity as a risk factor,
which showed an increased risk of death (30.1, 1.17 to 773.12).
The presence of chronic lung disease was associated with a
higher risk for admission to hospital and to an intensive care
unit, and the need for ventilator support. Asthma was only
associated with a higher risk of developing pneumonia, whereas
chronic obstructive pulmonary disease was associated with a
higher likelihood of needing ventilator support. Cardiovascular
disease increased the risk of death (1.97, 1.06 to 3.67, I2=46%,
n=8) as well as of pneumonia, hospital admission, and need for
ventilator support. Immunocompromised participants were at
higher risk for death (3.81, 1.28 to 11.35, I2=71%, n=4) but at
lower risk of developing pneumonia. The presence of any
neuromuscular disease was associated with a higher risk for
death (3.21, 1.84 to 5.58, I2=0%, n=4), whereas diabetes mellitus
but not any of the other risk factors of interest was associated
with a higher risk for hospital admission.
Pandemic influenza
Age as a risk factor
Elderly people were at higher risk for death compared with
younger adults during pandemic influenza (2.69, 1.53 to 4.71,
I2=86%, n=29 studies) (table 4). The summary estimate was
even greater when only community based studies were pooled
(6.35, 1.26 to 31.94, I2=93%, n=5). However, there was a large
overlap in the 95% confidence interval across subgroups,
specifically: 1.26 to 31.94 (I2=93%, n=4) in the community and
2.24 to 5.48 (I2=68%, n=16) in participants admitted to hospital.
Similarly there was overlap between 95% prediction intervals
in these settings: 0.01 to 2900 in the community and 0.87 to
14.07 in participants admitted to hospital. Elderly participants
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were also at higher risk for hospital admission but at lower risk
of being admitted to the intensive care unit.
In contrast, the risk of death in children (compared with
non-elderly adults) was reduced (0.28, 0.19 to 0.41, 95%
prediction interval 0.09 to 0.82, I2=39%, n=21). Again, the effect
was accentuated in community based studies (0.19, 0.10 to 0.36,
I2=39%, n=4), but with overlapping 95% prediction intervals
(0.02 to 1.49 in the community, 0.08 to 0.84 in the hospital, and
0.28 to 0.72 in the intensive care unit setting). Children aged
less than 5 years were at a higher risk of developing pneumonia
and requiring hospital admission but tended to be at lower risk
of death (0.59, 0.29 to 1.22, I2=49%, n=15) and were at a lower
risk for admission to an intensive care unit. Compared with
non-elderly adults, children were less likely to be admitted to
hospital with pandemic influenza.
Ethnicity
Despite the availability of a larger number of studies for
pandemic influenza than for seasonal influenza addressing
ethnicity as a potential risk factor, we found no significant
differences in all cause mortality among Asian, black, or native
populations compared with white participants. The only
significant difference was a higher risk for hospital admission
for black and Hispanic participants but a lower risk for
admission to an intensive care unit for black participants. For
Australian natives, the likelihood of hospital admission was
lower compared with white participants.
Pregnancy
Pregnancy did not increase the risk of death. However, pregnant
women were at higher risk for hospital admission but were not
at increased risk of pneumonia and, in fact, were at significantly
reduced risk of admission to an intensive care unit. In contrast,
women who were less than four weeks post partum had a
significantly increased risk of death (4.43, 95% confidence
interval 1.24 to 15.81, I2=0%, n=3). When compared with those
in the first or second trimester, women in the third trimester had
an increase in all cause mortality (1.22, 1.01-1.48, I2=0%, n=5).
Comorbidity
The presence of “any risk factor” was associated with higher
all cause mortality (2.77, 1.90 to 4.05, I2=88%, n=53) and also
with higher admission rates to hospital and an intensive care
unit. Reports on obesity as a risk factor from 59 studies showed
that obesity not only increased the risk of death (2.74, 1.56 to
4.80, I2=92%, n=33) but was significantly associated with the
need for admission to hospital and an intensive care unit, as
well as for ventilator support.
The presence of any chronic lung disease (1.71, 1.17 to 2.51,
I2=79%, n=27), chronic obstructive pulmonary disease (1.49,
1.15 to 1.92, I2=0%, n=13), or obstructive sleep apnoea (2.63,
1.25 to 5.52, I2=0%, n=2) also increased the risk for death. We
also found associations between the presence of any chronic
lung disease and admission to hospital as well as admission to
an intensive care unit, and between chronic obstructive
pulmonary disease and admission to an intensive care unit.
Cardiovascular disease increased the risk of death significantly
(2.92, 1.76 to 4.86, I2=89%, n=28).We also found an association
with admission to hospital and an intensive care unit. In contrast
with seasonal influenza, hypertension was associated with a
higher risk for death (1.49, 1.10 to 2.10, I2=0%, n=7).
Immunosuppression increased the risk of death from pandemic
influenza (3.67, 1.78 to 7.58, I2=94%, n=23), and
immunocompromised participants were more likely to be
admitted to hospital. Participants with malignancy (3.10, 2.35
to 4.10, I2=0%, n=12 for mortality) and neuromuscular disease
had an increased risk of death (2.68, 1.91 to 3.75, I2=25%, n=16).
Neurocognitive diseases were not significantly associated with
death but were with admission to hospital and an intensive care
unit and with ventilator support. Further risk factors found to
be associated with a higher risk of death included anaemia or
haemoglobinopathy, diabetes mellitus, and liver, metabolic, and
renal disease (table 4).
Heterogeneity
In most instances heterogeneity was due to differences in
magnitude rather than a different direction of the effect. Risk
estimates were typically highest in the community based
populations, lower in participants admitted to hospital, and
lowest in participants admitted to an intensive care unit, both
across studies in the meta-analysis and within studies. One
example was the presence of “any risk factor” for total mortality:
the study by Buda et al18 showed an odds ratio of 72.48 (95%
confidence interval 50.35 to 104.33) in the overall community
sample but only 19.18 (13.26 to 27.73) in the subgroup of
participants who needed hospital admission. In our
meta-analysis, we found an odds ratio of 10.06 (2.32 to 43.61,
I2=86%, n=9) in the community, 3.01 (2.01 to 4.51, I2=85%,
n=30) in participants admitted to hospital, and 1.56 (1.28 to
1.90, I2=9%, n=22) in participants admitted to an intensive care
unit. However, when considering the 95% prediction intervals,
there was a large overlap across the subgroups (0.08 to 1287.99,
0.50 to 17.97, and 1.09 to 2.21, respectively). Other than
stratification by population, our hypotheses to explain
heterogeneity were of limited value: data on vaccination was
often lacking, rendering subgrouping impossible, only a few
studies did not use laboratory confirmation of influenza, and
subgrouping by risk of bias was not helpful because most studies
(n=196, 75%) were in the middle range of risk of bias (4-6
Newcastle-Ottawa scale points).
Only a few risk factors were associated, significantly or at least
in a trend, with all outcomes of interest for both types of
influenza (table 5). With the exception of pneumonia in studies
during pandemic influenza, these included the presence of “any
risk factor,” obesity, and neuromuscular diseases. Chronic lung
diseases were associatedwith all outcomes other than pneumonia
and ventilator support during pandemic influenza.
Cardiovascular diseases were associated with all outcomes other
than pneumonia during pandemic influenza and admission to
an intensive care unit during seasonal influenza. Neurocognitive
disease was not associated with all cause mortality during
seasonal influenza, but was with all other outcomes with data
available.
Discussion
The evidence supporting risk factors for severe outcomes of
influenza ranges from being limited to absent. This was
particularly relevant in the relative lack of data for studies on
non-2009 H1N1 pandemics and for seasonal influenza. The
level of evidence was low for “any risk factor,” obesity,
cardiovascular diseases, and neuromuscular disease, and was
very low for all other risk factors.
Why the evidence was limited
There were widely accepted risk factors, such as pregnancy, as
well as more recently described risks, such as belonging to an
ethnic minority group, for which we could not find a trend for
higher rates of severe outcomes other than more frequent
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hospital admission. Given the lack of a demonstrable effect for
these comparisons despite large sample sizes, lack of power is
an unlikely explanation. On the other hand, we found positive
effects that did not reach statistical significance in some risk
factor-outcome comparisons for which there were only small
sample sizes. For example, the association between chronic lung
diseases and mortality during seasonal influenza (odds ratio 1.8,
95% confidence interval 0.81 to 4.01) was not statistically
significant. Calculating the optimal information size19 with
consideration of the heterogeneity found for this comparison,20
approximately 5000 participants would have been required in
each arm to detect a difference of 25% in mortality. Given that
only 1200 participants were available, the lack of statistical
significance was most likely due to a lack of power. Because
influenza vaccination was not adjusted for, the calculated risk
estimates may have underestimated the true effect size—for
example, because chronic lung disease is a well known risk
factor, participants with chronic lung diseases may have been
more likely to be vaccinated than the comparison group thus
mitigating the risk for severe outcomes in participants with
underlying chronic lung disease.We also found that such a lack
of adjustment for confounders was widespread: adjusted risk
estimates were provided for only 5.4% of risk factor-outcome
comparisons in 39 of 260 (15%) studies. Although such a lack
of adjusted risk estimates could potentially be misleading, we
did find similar effect sizes in those studies that reported both
adjusted and unadjusted risk estimates.
The relative lack of eligible studies on non-H1N1 pandemic
influenza and on seasonal influenza before 1991 was surprising.
Therefore the findings from the meta-analyses on pandemic
influenza cannot necessarily be extrapolated to non-H1N1
pandemic strains, and the findings on seasonal influenza cannot
necessarily be extrapolated to non-H3N2 and non-influenza B
strains.
Variability in definitions of risk factors and the potential for
differential ascertainment of risk factors possibly contributed
to the heterogeneity in the affected comparisons. Differing
lengths of follow-up may have also resulted in heterogeneity,
and studies that were deemed to have an inadequate length of
follow-up (16%) may have missed events and therefore biased
the results towards smaller effect sizes. Owing to the differing
length of follow-up used in the included studies, meta-analysis
of hazard ratios instead of odds ratios might have reduced
heterogeneity. In contrast with odds ratios, hazard ratios are
more likely to be constant over time.21 Unfortunately, hazard
ratios were rarely reported and thus meta-analysis of hazard
ratios was not feasible. Another limitation of the data was
inconsistency in outcomes—that is, for a given risk factor we
would have expected to see an increase in all types of severe
outcomes. Thus when evaluating risk factors with inconsistent
findings across outcomes, we downgraded the level of evidence.
The presence of poor quality of evidence in studies on prognostic
factors in general is well known22; we found a similar picture
for risk factors for severe outcomes with influenza in our study,
despite the important public health implications of these studies.
Interpretation of meta-analysis results
Our meta-analysis showed that elderly people had the highest
risk of death during both seasonal and pandemic influenza
seasons. In contrast, children and young people aged less than
18 years had a significantly reduced risk of death compared
with non-elderly adults during pandemics. Children aged less
than 5 years, in particular those aged 2 to less than 5 years, were
at increased risk of pneumonia from both pandemic and seasonal
influenza when compared with older children.23 24Age less than
2 years was not a risk factor for any outcome other than hospital
admission during pandemic influenza.
Pregnancy increased the risk of admission to hospital but not
for any of the other outcomes. In contrast, women in the
postpartum period were at higher risk for severe outcomes.25 26
In studies comparing the third trimester of pregnancy with the
first and second trimesters, the third trimester placed women at
higher risk of severe outcomes.27 28 These data suggest that risk
increases in the late stages of pregnancy.29 30Notably, the results
of ongoing systematic reviews on adverse effects, outcomes,
and effectiveness of influenza vaccination in pregnancy will be
of interest.31 32 Our findings are in keeping with
recommendations to prioritise vaccination of pregnant women
because of the increased risk for mortality post partum, and
elderly people. In contrast, we did not found convincing
evidence to prioritise vaccination of young children compared
with adults.
Our findings also suggest that obesity (body mass index >30)
is an important cause of death with both pandemic and seasonal
influenza.28 33 It remains unclear whether obesity in itself is a
risk factor or whether it reflects the presence of other
comorbidities such as cardiovascular diseases and diabetes
mellitus.34However, morbid obesity was identified as a potential
independent risk factor after adjustment for these
comorbidities.33
It has been suggested that certain ethnic groups may have been
at higher risk for severe outcomes due to influenza during the
2009 pandemic30; however, we found no significant differences
in all cause mortality among Asian, black, or native populations
comparedwith white participants for either seasonal or pandemic
influenza.28-36Hispanic and black participants as well as pregnant
women were more likely to have been admitted to hospital
during the 2009 H1N1 pandemic but were at lower risk for more
severe outcomes.28 37 It may be that because of a perception
among healthcare providers of an increased risk of complications
that these groups were selectively admitted to hospital during
the 2009 H1N1 pandemic. This is in contrast with seasonal
influenza where people of Hispanic ancestry were almost half
as likely to be admitted to hospital.
As expected, chronic illness, including immunosuppression,
cardiovascular disease, chronic lung disease, neuromuscular
disease, neurological disease, chronic renal disease, and
metabolic diseases increased the risk of mortality from influenza.
Mortality did not differ among the sexes.
We found slightly greater effect sizes in community based
studies compared with hospital based and intensive care unit
based studies. We speculate that this is because heterogeneity
among participants in community based studies is greater than
among participants admitted to hospital—that is, participants
admitted to hospital may share a level of comorbidity that, apart
from the risk factor in question, leads to more similar
outcomes.38 An overlap did occur in the prediction intervals in
these instances, either due to heterogeneity or due to the small
number of studies available. It thus remains uncertain whether
these differences were due to chance alone.
Strengths and limitations of this review
Strengths of this reviewwere the comprehensive search strategy,
the extensive amount of data reviewed, the assessment for study
quality, the high percentage of studies using laboratory
confirmation to diagnose influenza, and the breadth of outcomes
and risk factors examined. In addition to the limitations of the
included studies, it should be noted that the GRADE
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methodology used was developed to assess quality of evidence
for interventions and not for prognostic factors. Therefore it
remains unclear whether similar standards need to apply to the
types of studies in this review because randomised controlled
trials on risk factors are not feasible and therefore a high level
of evidence according to GRADEmethodology is unlikely ever
to be achieved.10
Implications of the findings
Policy makers and public health organisations such as WHO
should acknowledge the poor quality of evidence supporting
vaccine recommendations for those deemed to be at high risk
from influenza and to outline the level of evidence in their
vaccination recommendations. This is of particular relevance
when vaccine supply is insufficient. Obesity and the postpartum
period were identified as potentially important risk factors that
should be included in future vaccination recommendations.
Given the limited level of evidence, however, any well designed
and adequately powered and conducted study is likely to affect
the conclusions of this systematic review. This being said, our
findings highlight the importance of conducting rigorous studies
and of adequately reporting the results when assessing
complications due to influenza.
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What is already known on this topic
Certain patient populations are thought to be at higher risk for developing complicated or severe influenza illness
These groups are prioritised for vaccination as well as for antiviral treatment
What this study adds
The quantity and quality of evidence on risk factors for developing complicated or severe influenza illness is limited
While some risk factors could be corroborated, evidence to support other, well established risk factors for severe outcomes could not
be found
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Tables
Table 1| CurrentWorld Health Organization and Center for Disease Control and Prevention (CDC) recommendations for influenza vaccination
CDCWHO
Groups Seasonal 20112Seasonal 20125Pandemic 20096
RecommendedRecommended1Healthcare workers
Recommended12Pregnant women
—Recommended3Aged >6 months with “chronic medical conditions”
Recommended——Aged >6 months with specific chronic medical
conditions*
Recommended——Aged 6 months to 18 years and receiving long term
aspirin treatment
Healthy people:
RecommendedRecommended—Young children (6-59 months)
——5Healthy children
——4Young adults (>15 and <49 years)
——6Adults (>40 and <65 years)
Recommended——Adults (≥50 years)
—Recommended7Adults (>65 years)
Recommended——Residents of nursing homes and other chronic care
facilities
Recommended——American Indians/Alaska Natives
Recommended——Morbidly obese (body mass index ≥40)
Recommended——Household contacts and caregivers of children aged
<5 years and adults aged ≥50 years or of people with
high risk conditions
Numbers indicate priority level (where applicable), recommended indicates vaccination recommendation.
CDC recommends routine vaccination of all individuals aged 6 months and older. The table summarises groups prioritised by CDC in the setting of limited vaccine
supply.
*Chronic pulmonary including asthma, cardiovascular except hypertension, renal, hepatic, neurological, haematological, metabolic including diabetes mellitus,
immunosuppressed.
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Table 2| Study characteristics of 239 studies in 234 included articles. Values are numbers (percentages) unless stated otherwise
Seasonal influenzaPandemic influenzaOverallCharacteristics














75 871534 911610 782No of participants
52 (93)171 (93)223 (93)English articles
Geographical region:
32 (57)50 (27)82 (34)North America
9 (16)49 (27)58 (24)Europe
1 (2)24 (13)25 (10)Central/South America
10 (18)39 (21)49 (21)Asia
4 (7)21 (12)25 (10)Others
56 (100)175 (96)231 (97)Cohort studies
47 (84)173 (95)220 (92)Laboratory confirmation of influenza
Median (range) Newcastle-Ottawa scale points:
6 (3-8)6 (1-8)6 (1-8)Overall
3 (2-4)3 (1-4)3 (1-4)Selection of study groups
0 (0-1)0 (0-1)0 (0-1)Comparability of groups
3 (0-3)3 (0-3)3 (0-3)Ascertainment of diseases
NA=not applicable.
If reporting across more than one 10 year band, the band with the most participants was chosen.
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Table 3| Summary estimates for seasonal influenza. Values are odds ratios (95% confidence intervals), I2 (%), and number of studies






0.96 (0.69 to 1.34), 23, n=131.18 (0.37 to 3.73),
NA, n=1
1.50 (0.17 to 13.23),
NA, n=1
1.26* (1.07 to 1.47), 17,
n=5
1.22 (0.82 to 1.81), 23, n=6Male sex
2.95* (1.53 to 5.70), 11, n=4NANA4.65* (1.74 to 12.41), 71,
n=2
1.48 (0.21 to 10.57), 0, n=2Elderly v non-elderly adults
1.48 (0.37 to 5.93), 21, n=3NANANA0.41 (0.01 to 11.46), NA,
n=1
Paediatric† v non-elderly adults
0.53 (0.21 to 1.34), 0, n=3NANA0.51* (0.34 to 0.76), NA,
n=1
1.74* (1.39 to 2.17), 0, n=22-<5 years v 5-<18 years
0.40* (0.20 to 0.80), 0, n=80.47* (0.26 to 0.86),
0, n=2
0.57 (0.27 to 1.18),
58, n=2
0.58* (0.43 to 0.78), 82,
n=4
1.53* (1.06 to 2.20), 65,
n=5
<5 years v 5-<18 years
0.76 (0.26 to 2.24), 67, n=80.55* (0.28 to 0.88),
0, n=2
0.62* (0.43 to 0.89),
0, n=3
0.59* (0.47 to 0.75), 0,
n=2
0.66 (0.41 to 1.07), 75, n=5<2 years v 2-<18 years
1.30 (0.41 to 4.05), 1, n=30.61 (0.31 to 1.21),
0, n=3
0.56* (0.35 to 0.89),
0, n=4
1.18 (0.97 to 1.44), 0,
n=2
0.39* (0.29 to 0.52), 14,
n=4
<6 months v <6 months to 2
years
Ethnicity:
NANANA1.55 (0.94 to 2.55), NA,
n=1
1.22 (0.79 to 1.87), NA,
n=1
Asian/Pacific v white
7.22 (0.28 to 189.19), 11, n=1NANA2.06 (0.75 to 5.63), NA,
n=1
1.16 (0.95 to 1.40), 0, n=2Black v white
NANANA0.56* (0.43 to 0.73), NA,
n=1
1.20 (0.98 to 1.47), 0, n=2Hispanic v white
NANANA0.70 (0.23 to 2.17), NA,
n=1
NANative American v white
NANANANANANative Australian v white
Pregnancy and postpartum period:
1.07 (0.79 to 1.45), 0, n=2NANANANAPregnancy
NANANANANA<4 weeks post partum
NANANANANA3rd trimester v 1st or 2nd
trimester
2.04* (1.74 to 2.39), 0, n=141.71 (0.99 to 2.96),
30, n=4
1.74* (1.32 to 2.29),
0, n=3
3.39* (2.60 to 4.42), 92,
n=3
1.53* (1.04 to 2.24), 11,
n=7
Any risk factor or comorbidity
Weight (body mass index):





1.80 (0.81 to 4.01), 52, n=64.02* (1.69 to 9.58),
NA, n=1
4.46* (1.34 to 14.79),
NA, n=1
2.38* (1.58 to 3.57), NA,
n=1
1.94 (0.45 to 8.42), 52, n=3Any chronic lung disease
0.89 (0.10 to 7.71), 0, n=2NA1.39 (0.28 to 6.81),
NA, n=1
NA1.35* (1.12 to 1.62), NA,
n=1
Asthma






1.97* (1.06 to 3.67), 46, n=83.31* (1.03 to
10.61), NA, n=1
1.09 (0.30 to 4.01),
NA, n=1
16.45* (9.89 to 27.37),
NA, n=1
1.56* (1.06 to 2.28), 0, n=3Any cardiovascular disease
3.53 (0.32 to 38.87), 0, n=2NANANANAHypertension
1.27 (0.16 to 10.07), NA, n=1NANANANACerebrovascular insult
Immunosuppression:
3.81* (1.28 to 11.35), 71, n=4NA0.25 (0.06 to 1.12),
NA, n=1
NA0.61* (0.42 to 0.89), 60,
n=3
Immunocompromised host
3.87 (0.52 to 28.96), NA, n=1NANANANAHIV
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Table 3 (continued)





1.79 (0.66 to 4.87), NA, n=1NANA17.49* (6.97 to 43.92),
NA, n=1
NAChronic steroid therapy
2.67 (0.22 to 32.23), NA, n=1NANA19.35* (10.55 to 35.48),
NA, n=1




3.21* (1.84 to 5.58), 0, n=4NANANA1.57 (1.05 to 2.36), NA,
n=1
Any neuromuscular disease
1.33 (0.33 to 5.33), 0, n=2NA2.07 (0.75 to 5.72),
NA, n=1
NA1.45* (1.05 to 1.99), NA,
n=1
Neurocognitive disease




0.13 (0.01 to 2.34), NA, n=1NANANA0.47 (0.07 to 2.96), NA,
n=1
Alcohol with or without illicit drug
use
NANA0.12 (0.01 to 1.99),
NA, n=1




0.59 (0.23 to 1.50), 0, n=2NANA9.91* (5.46 to 17.99),
NA, n=1
0.91 (0.26 to 3.24), 0, n=2Diabetes mellitus




0.38 (0.04 to 3.98), NA, n=1NANANANALiver disease
0.52 (0.12 to 2.21), NA, n=1NANANA0.89 (0.53 to 1.50), NA,
n=1
Metabolic disease
NANANANANAPrematurity or preterm birth
2.16 (0.58 to 8.08), 0, n=20.68 (0.08 to 5.66),
NA, n=1
NANA1.25 (0.70 to 2.23), 0, n=3Renal disease
NA=not applicable (only one study reporting on this risk factor-outcome comparison).
*Statistically significant.
†Children up to 18 years of age or as defined by original study.
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Table 4| Summary estimates for pandemic influenza with odds ratios (95% confidence intervals), I2 (%), and number of studies






1.04 (0.94 to 1.16), 5, n=641.31 (0.80 to 2.12), 0,
n=15
0.93 (0.86 to 1.01), 0, n=190.99 (0.93 to 1.05), 24,
n=12
1.23 (0.99 to 1.52), 0,
n=10
Male sex
2.69* (1.53 to 4.71), 86,
n=29
0.71 (0.28 to 1.77), 0,
n=7
0.62* (0.39 to 1.00), 36, n=62.84* (1.76 to 4.59), 84,
n=7
1.67 (0.36 to 7.77), 74,
n=3
Elderly v non-elderly adults
0.28* (0.19 to 0.41), 39,
n=21
0.68 (0.35 to 1.31), 0,
n=7
0.65 (0.33 to 1.26), 73, n=70.79* (0.64 to 0.98), 72,
n=7




0.46 (0.20 to 1.07), 38, n=71.29 (0.59 to 2.85), 0,
n=2
0.79* (0.64 to 0.97), 0, n=70.96 (0.52 to 1.75), 0, n=22.05* (1.26 to 3.33), 0,
n=2
2-<5 years v 5-<18 years
0.59 (0.29 to 1.22), 49,
n=15
0.97 (0.52 to 1.82), 0,
n=6
0.66* (0.53 to 0.84), 23,
n=12
2.97* (2.55 to 3.45), 24,
n=6
1.56* (1.07 to 2.26), 0,
n=3
<5 years v 5-<18 years
0.53 (0.17 to 1.64), 0, n=60.74 (0.26 to 2.08), 25,
n=4
0.53* (0.37 to 0.75), 0, n=55.38 (0.45 to 64.52), NA,
n=1
1.05 (0.71 to 1.55), 0,
n=3
<2 years v 2-<18 years
1.00 (0.17 to 5.98), NA, n=13.33 (0.03 to 343.77),
69, n=2
1.83 (0.47 to 7.11), 0, n=2NA, NA1.03 (0.20 to 5.37), 0,
n=2
<6 months v 6 months to
<2 years
Ethnicity:
0.64 (0.40 to 1.03), 0, n=5NA1.12 (0.61 to 2.08), 0, n=41.60 (0.91 to 2.70), 0, n=2NAAsian/Pacific v white
0.70 (0.42 to 1.18), 11, n=6NA0.53* (0.36 to 0.78), 0, n=52.19* (1.52 to 3.16), 0, n=3NABlack v white
0.76 (0.48 to 1.19), 36, n=4NA0.80 (0.57 to 1.14), 0, n=41.93* (1.38 to 2.70), 0, n=3NAHispanic v white
0.93 (0.67 to 1.30), 0, n=4NA0.95 (0.79 to 1.13), 0, n=53.07 (0.62 to 15.20), NA,
n=1
1.49 (0.56 to 3.92), NA,
n=1
Native American v white
0.57 (0.12 to 2.69), 47, n=3NA0.91 (0.73 to 1.14), 0, n=30.40* (0.21 to 0.75), NA,
n=1
NANative Australian v white
Pregnancy and postpartum
period:
0.99 (0.67 to 1.46), 62,
n=26
1.12 (0.42 to 2.99), 58,
n=8
0.62* (0.52 to 0.75), 67,
n=19
3.50* (1.65 to 7.40), 90,
n=7
1.13 (0.76 to 1.67), 69,
n=7
Pregnancy
4.43* (1.24 to 15.81), 0, n=31.43 (0.33 to 6.32), NA,
n=1
2.34 (0.56 to 9.82), NA, n=1NA3.62 (0.42 to 30.9), NA,
n=1
<4 weeks post partum
1.22* (1.01 to 1.48), 0, n=5NA1.48* (1.05 to 2.09), 0, n=33.98* (1.65 to 9.57), 88,
n=2
0.97 (0.78 to 1.20), NA,
n=1
3rd trimester v 1st or 2nd
trimester
2.77* (1.90 to 4.05), 88,
n=53
1.60 (0.96 to 2.69), 12,
n=14
1.93* (1.59 to 2.35), 63,
n=27
2.73* (1.89 to 3.95), 95,
n=14
1.19 (0.64 to 2.22), 61,
n=10
Any risk factor or
comorbidity
Weight (body mass index):
2.74* (1.56 to 4.80), 92,
n=33
1.79* (1.38 to 2.32), 0,
n=9
1.81* (1.48 to 2.22), 48,
n=16
3.44* (2.14 to 5.54), 71,
n=8
1.44 (0.99 to 2.10), NA,
n=1
Obese (>30)
1.35 (0.43 to 4.22), NA, n=10.56 (0.16 to 1.98), NA,
n=1
1.26 (0.52 to 3.04), n NA,
n=1




1.71* (1.17 to 2.51), 79,
n=27
1.06 (0.35 to 3.15), 0,
n=5
1.48* (1.19 to 1.83), 47, n=22.37* (1.56 to 3.61), 89,
n=9
1.19 (0.12 to 11.44), 0,
n=2
Any chronic lung disease
0.92 (0.49 to 1.28), 31,
n=21
0.91 (0.36 to 2.31), 0,
n=9
0.83 (0.59 to 1.17), 25, n=181.40 (0.96 to 2.03), 42, n=41.88 (0.87 to 4.08), 0,
n=4
Asthma
1.49* (1.15 to 1.92), 0, n=132.46 (0.62 to 9.74), 371.84* (1.40 to 2.41), 50, n=58.00 (0.58 to 110.27), NA,
n=1








2.92* (1.76 to 4.86), 89,
n=28
1.66 (0.78 to 3.56), 0,
n=7
1.70* (1.39 to 2.08), 55,
n=17
3.54* (2.29 to 5.47), 71,
n=9




1.49* (1.10 to 2.01), 0, n=70.82 (0.19 to 3.50), 0,
n=3
0.87 (0.49 to 1.58), 0, n=40.80 (0.24 to 2.65), NA,
n=1
NAHypertension
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Table 4 (continued)





3.67* (1.78 to 7.58), 94,
n=23
1.40 (0.43 to 4.53), 0,
n=5
1.02 (0.78 to 1.33), 28, n=164.61* (2.41 to 8.82), 85,
n=11
0.56 (0.12 to 2.56), NA,
n=1
Immunocompromised host
0.97 (0.47 to 1.99), 7, n=90.80 (0.25 to 2.58), 0,
n=4
0.94 (0.28 to 3.22), NA, n=1NA1.78 (0.90 to 3.53), 0,
n=2
HIV
1.54 (0.69 to 3.44), NA, n=1NA0.83 (0.28 to 2.48), NA, n=22.19 (0.20 to 24.38), NA,
n=1
NAChronic steroid therapy
3.10* (2.35 to 4.10), 0, n=121.46 (0.47 to 4.51), 0,
n=5
1.37 (0.99 to 1.90), 50, n=94.77* (2.10 to 10.83), 0,
n=3




2.68* (1.91 to 3.75), 25,
n=16
1.93 (0.67 to 5.54), 26,
n=4
2.63* (1.83 to 3.79), 0, n=82.64* (1.57 to 4.43), 15,
n=6




5.01 (0.48 to 52.34), 97,
n=8
5.90* (1.21 to 28.77),
30, n=2
2.26* (1.49 to 3.45), 0, n=414.69* (8.96 to 24.08), 0,
n=2
NANeurocognitive disease
1.46 (0.93 to 2.31), 0, n=71.31 (0.10 to 16.55), 14,
n=2
1.51 (0.59 to 3.83), 54, n=34.76* (1.61 to 14.02), NA,
n=1




6.48 (0.95 to 44.16), 0, n=2NA1.70 (0.59 to 4.89), NA, n=13.57 (0.32 to 39.92), NA,
n=1
0.57 (0.15 to 2.12), NA,
n=1
Alcohol with or without
illicit drug use
2.28* (1.35 to 3.84), 0, n=80.28 (0.03 to 2.82), 0,
n=2
1.28 (0.54 to 3.08), 0, n=36.55* (2.32 to 18.52), 0,
n=3




4.96 (0.41 to 60.6), 58, n=30.81 (0.03 to 22.24),
NA, n=1
29.05* (1.49 to 567.79), NA,
n=1
3.73 (0.82 to 17.06), 0, n=2NAAutoimmune disease
2.21* (1.37 to 3.57), 86,
n=32
1.54 (0.60 to 3.91), 0,
n=8
1.60* (1.32 to 1.94), 37,
n=18
4.26* (3.14 to 5.77), 31,
n=9
0.97 (0.30 to 3.12), 0,
n=2
Diabetes mellitus
NANA1.49 (0.18 to 12.45), NA,
n=1
4.00* (2.23 to 7.18), NA,
n=1
NAEndocrinological disease
0.97 (0.60 to 1.59), 23, n=2NA0.47 (0.06 to 3.93), NA, n=11.47 (0.15 to 14.36), NA,
n=1
NAGastrointestinal disease
2.00* (1.32 to 3.04), 22, n=88.11 (0.17 to 377.11),
66, n=2
2.65* (1.44 to 4.88), 0, n=61.93 (0.29 to 12.72), 0, n=2NALiver disease
1.83* (1.19 to 2.79), 54, n=414.22* (3.35 to 60.34),
NA, n=1
2.77 (0.36 to 21.33), 65, n=20.62 (0.17 to 2.24), 0, n=20.66 (0.17 to 2.53), NA,
n=1
Metabolic disease
1.94 (0.76 to 4.98), 0, n=410.41* (1.02 to 106.13),
0, n=2
1.25 (0.47 to 3.31), 87, n=231.59* (1.80 to 552.94),
NA, n=1




3.11* (1.54 to 6.28), 90,
n=16
1.65 (0.07 to 36.96), 70,
n=3
1.27 (0.88 to 1.84), NA,
n=11
5.11* (2.50 to 10.42), 46,
n=5
0.20 (0.01 to 5.57), NA,
n=1
Renal disease
NA=not applicable (only one study reporting on this risk factor-outcome comparison).
*Statistically significant.
†Children up to 18 years of age or as defined by original study.
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Table 5| Risk estimates of identified risk factors during pandemic (p) and seasonal (s) influenza, and assessment of quality of evidence

























Very lowUpDownDownNA+NANtrlNA*NANANA*<4 weeks post partum
Very lowDownNA+NANANA+NA+NANtrl3rd trimester v 1st/2nd
trimester
Very lowUpDownDownNA*NA+NANtrlNA+NA*Prematurity or preterm
birth
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GRADE=grading of recommendations assessment, development, and evaluation; COPD=chronic obstructive pulmonary disease; +=significant risk factor; *potential
risk factor: odds ratio >1.5, trend; Ntrl=neutral; (*)=potentially protective: odds ratio <0.67, trend, (+)=significant protective factor; NA=not available.
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Figure
Flow of studies included and excluded
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